Actively Recruiting
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
Led by University of Florida · Updated on 2026-04-06
68
Participants Needed
1
Research Sites
133 weeks
Total Duration
On this page
Sponsors
U
University of Florida
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Much of human interaction is based on trust. Aging has been associated with deficits in trust-related decision making, likely further exacerbated in age-associated neurodegenerative disease (Alzheimer's disease/AD), possibly underlying the dramatically growing public health problem of elder fraud. Optimal trust-related decision making and avoiding exploitation require the ability to learn about the trustworthiness of social partners across multiple interactions, but the role that learning plays in determining age deficits in trust decisions is currently unknown. Aim: Probe the malleability of the underlying neurocircuitry of trust-learning deficits in aging. This study will utilize real-time fMRI neurofeedback to train older adults in brain activity up-regulation toward enhanced trust-related learning in aging and confirm critical mechanisms of experience-dependent social decisions in aging. Grant R01AG072658 Aim 3: Test the malleability of trust-learning neurocircuitry toward optimized trust-related decision making in aging.
CONDITIONS
Official Title
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide verbal and written informed consent
- Fluent English speaker
- At least 8th grade education
- On stable medication regimen
You will not qualify if you...
- Pregnancy
- Magnetic resonance imaging contraindications (e.g., certain metallic objects in body, claustrophobia)
- Current major depression defined as scores >14 on the Beck Depression Inventory-II
- Impaired scores on the Telephone Interview for Cognitive Status (TICS; cut-off of >30)
- Current use of medications with significant anticholinergic properties due to potential influence on memory (e.g., Aricept or Namenda)
- Current use of anticonvulsant, neuroleptic, sedatives, or other medications known to affect cognition
- Uncorrected visual and hearing impairments
- Neurologic conditions affecting the brain (e.g., severe stroke, epilepsy, traumatic brain injury with >30-minute loss of consciousness)
- Impaired scores on the Montreal Cognitive Assessment (MoCA); cutoff will be age and education corrected
- Unstable medical illness (e.g., metastatic cancer)
- Significant cardiovascular conditions (e.g., major heart attack)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Florida
Gainesville, Florida, United States, 32611
Actively Recruiting
Research Team
D
Dana Arnold, M.S.
CONTACT
R
Ryan Faulkner
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here